2017 China M&A review – pharmaceuticals & medical devices sector
This issue is provided by PwC China’s Healthcare Consulting Team, highlighting M&A trends in China's two leading health-related industry sectors, pharmaceuticals and medical devices.
In 2017, China pharmaceutical sector M&A volume fell by 17% to US$17.12 billion, but mainland outbound activity increased by 10% and 97% in number of deals and in deal value. Meanwhile, in the medical device sector, M&A volume fell by 36% in 2017 to US$4.94 billion, the lowest amount in the past three years. For further discussion on these topic, please contact Audrey Tseng.
Follow us
